- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
24 result(s) found for: Medical toxicology.
Displaying page 1 of 2.
EudraCT Number: 2015-003035-35 | Sponsor Protocol Number: HS-14-499 | Start Date*: 2015-11-09 |
Sponsor Name:Braeburn Pharmaceuticals | ||
Full Title: An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioi... | ||
Medical condition: Opioid Use Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) DK (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000189-12 | Sponsor Protocol Number: ABR43234 | Start Date*: 2013-03-14 |
Sponsor Name:University Medical Centre Nijmegen | ||
Full Title: Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001817-35 | Sponsor Protocol Number: 111958 | Start Date*: 2021-08-04 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial. | ||
Medical condition: Opioid use disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000322-21 | Sponsor Protocol Number: TIP5 | Start Date*: 2012-05-29 |
Sponsor Name:Sanaria Inc. | ||
Full Title: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis | ||
Medical condition: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005343-27 | Sponsor Protocol Number: Metformin-FMD001 | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Can metformin prevent endothelial ischemia and reperfusion injury? The Metformin-FMD trial. | |||||||||||||
Medical condition: ischemia and reperfusion injury endothelial dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003787-48 | Sponsor Protocol Number: BP41674 | Start Date*: 2020-06-11 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME | |||||||||||||
Medical condition: Angelman Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001833-29 | Sponsor Protocol Number: 202152 | Start Date*: 2016-09-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and... | |||||||||||||
Medical condition: Active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000912-13 | Sponsor Protocol Number: 203168 | Start Date*: 2016-08-30 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in s... | |||||||||||||
Medical condition: subjects with moderate to severe rheumatoid arthritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000363-24 | Sponsor Protocol Number: Met-Dipy001 | Start Date*: 2012-04-18 | ||||||||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | ||||||||||||||||||
Full Title: The effect of dipyridamole on the pharmacokinetics of metformin. | ||||||||||||||||||
Medical condition: The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or s... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-006200-33 | Sponsor Protocol Number: CLA-PSY-201 | Start Date*: 2022-09-22 | |||||||||||
Sponsor Name:Clairvoyant Therapeutics Inc. | |||||||||||||
Full Title: A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with A... | |||||||||||||
Medical condition: Alcohol use disorder (AUD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002190-35 | Sponsor Protocol Number: 20150288 | Start Date*: 2017-01-11 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
Medical condition: High-risk Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006191-11 | Sponsor Protocol Number: E2007-G000-304 | Start Date*: 2017-02-13 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial S... | ||
Medical condition: Refractory Partial Seizures | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-001039-38 | Sponsor Protocol Number: 2016GA03 | Start Date*: 2017-09-14 | |||||||||||
Sponsor Name:University of Dundee/NHS Tayside | |||||||||||||
Full Title: A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment – ADVANCE HCV Study | |||||||||||||
Medical condition: Hepatitis C virus infection | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003778-34 | Sponsor Protocol Number: VIP578 | Start Date*: 2016-01-13 | |||||||||||
Sponsor Name:Volution Immuno Pharmaceuticals (UK) Ltd | |||||||||||||
Full Title: Coversin in Paroxysmal Nocturnal Haemoglobulinuria (PNH) in patients with resistance to Eculizumab due to complement C5 Polymorphisms | |||||||||||||
Medical condition: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005254-30 | Sponsor Protocol Number: EuRhythDiaII | Start Date*: 2013-12-27 | ||||||||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | ||||||||||||||||||
Full Title: Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers | ||||||||||||||||||
Medical condition: Insomnia because of disturbed sleep-work-rhythm | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003124-16 | Sponsor Protocol Number: KH176-204 | Start Date*: 2021-01-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. | ||
Medical condition: Genetically confirmed mitochondrial disease | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006169-33 | Sponsor Protocol Number: E2007-G000-306 | Start Date*: 2008-07-17 |
Sponsor Name:Eisai Ltd | ||
Full Title: Estudio doble ciego, controlado con placebo, con aumento gradual de dosis, en grupos paralelos para evaluar la eficacia y la seguridad de E2007 (perampanel) administrado como terapia adyuvante en p... | ||
Medical condition: Epilepsia: crisis parciales refractarias con o sin crisis secundarias generalizadas Epilepsy - refractory partial seizures with or without secondary generalisation | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) CZ (Completed) PT (Completed) HU (Completed) EE (Completed) LT (Completed) PL (Completed) LV (Completed) IT (Completed) BG (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000832-23 | Sponsor Protocol Number: KH176-203 | Start Date*: 2021-07-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutatio... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001089-33 | Sponsor Protocol Number: 2007-001089-33 | Start Date*: 2008-09-23 | |||||||||||||||||||||
Sponsor Name:University Medical Center Groningen, dept. of Cardiology [...] | |||||||||||||||||||||||
Full Title: Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects again... | |||||||||||||||||||||||
Medical condition: Myocardial ischemia-reperfusion injury. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000599-40 | Sponsor Protocol Number: KH176-202 | Start Date*: 2019-10-23 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirme... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
